Patient Prefer Adherence. 2016 Apr 22;10:613-9. doi: 10.2147/PPA.S99718. eCollection 2016.

Medication risk communication with cancer patients in a Middle East cancer care setting.

Patient preference and adherence

Kerry Wilbur, Maha Al-Okka, Ebaa Jumaat, Nesma Eissa, Merwa Elbashir, Sumaya M Al Saadi Al-Yafei

PMID: 27175061 PMCID: PMC4854243 DOI: 10.2147/PPA.S99718

Abstract

PURPOSE: Cancer treatments are frequently associated with adverse effects, but there may be a cultural reluctance by care providers to be forthcoming with patients regarding these risks for fear of promoting nonadherence. Conversely, research in a number of countries indicates high levels of patient desire for this information. We sought to explore cancer patient experiences, satisfaction, and preferences for medication risk communication in a Middle East care setting.

METHODS: We developed and administered a ten-item questionnaire (Arabic and English) to a convenience sample of consenting adult patients receiving treatment at the National Center for Cancer Care and Research in Qatar.

RESULTS: One hundred and forty-three patients were interviewed. Most (88%) stated that the level of side effect information they received was sufficient, with physicians (86%) followed by pharmacists (39%) as the preferred sources. The majority (97%) agreed that knowing about possible side effects would help them recognize and manage the reaction, and 92% agreed that it would help them understand how to minimize or prevent the risks. Eighteen percent indicated that this information would make them not want to take treatment. Two-thirds (65%) had previously experienced intolerance to their cancer treatment regimen.

CONCLUSION: Most patients surveyed expressed preference for the details of possible side effects they may encounter in their treatment. However, one in five considered such information a factor for nonadherence, indicating the need for patient-specific approaches when communicating medication risks.

Keywords: Middle East; cancer treatment; risk communication

References

1. Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1071-8 - PubMed
2. BMJ. 1999 Jan 30;318(7179):318-22 - PubMed
3. J Cancer Educ. 2012 Mar;27(1):46-53 - PubMed
4. Global Health. 2012 May 31;8:12 - PubMed
5. Ann Oncol. 1999 Sep;10(9):1095-100 - PubMed
6. Cancer Treat Rev. 2015 Feb;41(2):197-215 - PubMed
7. Health Expect. 2011 Mar;14(1):92-104 - PubMed
8. Patient Educ Couns. 2012 Nov;89(2):345-52 - PubMed
9. Lancet Oncol. 2012 Nov;13(11):e501-8 - PubMed
10. Support Care Cancer. 2014 Apr;22(4):999-1007 - PubMed
11. Br J Health Psychol. 2014 May;19(2):240-57 - PubMed
12. Ann N Y Acad Sci. 1997 Feb 20;809:163-71 - PubMed
13. Lancet Oncol. 2004 Feb;5(2):119-24 - PubMed
14. Ann Oncol. 2011 Apr;22(4):761-72 - PubMed
15. BMJ Open. 2015 Apr 01;5(4):e006890 - PubMed
16. Cancer Pract. 1998 Jan-Feb;6(1):39-46 - PubMed
17. East Mediterr Health J. 2009 Jan-Feb;15(1):19-24 - PubMed
18. Int J Pharm Pract. 2013 Aug;21(4):226-32 - PubMed
19. Patient Educ Couns. 2005 Jun;57(3):342-9 - PubMed
20. Ann N Y Acad Sci. 1997 Feb 20;809:7-16 - PubMed
21. Eur J Oncol Nurs. 2008 Apr;12(2):120-6 - PubMed
22. Eur J Oncol Nurs. 2006 Sep;10(4):273-82 - PubMed
23. Health Psychol Rev. 2014;8(4):490-508 - PubMed
24. Patient Educ Couns. 2005 Jun;57(3):250-61 - PubMed
25. Eur J Cancer. 2004 Aug;40(12):1850-4 - PubMed
26. Support Care Cancer. 2014 Sep;22(9):2457-64 - PubMed
27. Breast. 2013 Oct;22(5):661-6 - PubMed
28. PLoS One. 2012;7(9):e45921 - PubMed
29. Psychooncology. 2007 Mar;16(3):249-54 - PubMed
30. Eur J Oncol Nurs. 2014 Feb;18(1):46-51 - PubMed
31. Patient Educ Couns. 2013 Jan;90(1):96-102 - PubMed
32. Br J Cancer. 2007 Mar 12;96(5):744-51 - PubMed
33. J Cancer Educ. 2012 Dec;27(4):631-40 - PubMed
34. Psychooncology. 2013 Dec;22(12):2729-35 - PubMed
35. J Pediatr Hematol Oncol. 2011 Oct;33 Suppl 2:S81-6 - PubMed
36. Patient Educ Couns. 2009 Mar;74(3):287-94 - PubMed
37. J Cancer Educ. 2005 Summer;20(2):113-8 - PubMed
38. J Cancer Surviv. 2012 Sep;6(3):239-50 - PubMed

Publication Types

• Journal Article